01756nas a2200409   4500000000100000008004100001260000900042653002200051653002600073653001100099653001100110653001200121653001500133653001700148653001300165653001600178653000900194100001300203700001500216700001700231700001500248700001600263700001300279700001400292700001500306700002000321700001800341700001500359700001700374700002500391245002400416300001100440490000700451050001500458520085900473022001401332       1970                            d  c197010aAniline Compounds10aAnti-Infective Agents10aHumans10aImines10aleprosy10aPhenazines10aSulfonamides10aSulfones10aThalidomide10aUrea1 aConvit J1 aBrowne S G1 aLanguillon J1 aPettit J H1 aRamanujam K1 aSagher F1 aSheskin J1 aTarabini G1 aDE SOUZA LIMA L1 aTolentino J G1 aWaters M F1 aBechelli L M1 aMartinez Dominguez V00aTherapy of leprosy.  a667-720 v42  aCONVIT19703 a<p>The latest developments and ideas in the therapy of leprosy are discussed, the need for long-term studies being stressed. The therapeutic efficacy and effective dosages of some sulfones (especially diaphenylsulfone), thiambutosine and long-acting sulfonamides such as sulfamethoxine and sulfalene, are considered. The possibilities for two newer drugs, 4,4'-diacetyldiaminodiphenylsulfone and clofazimine (B-663), both still in the early stages of evaluation, are also described and the potential value of thalidomide in treatment of the lepra reaction is discussed. The authors make a number of recommendations for controlled trials and lines of investigation and, in particular, favour a biochemical approach to the correction of defective host defences. Diaphenylsulfone is still considered the drug of choice for use in the therapy of leprosy.</p>  a0042-9686